Skip to main content

Prime Medicine, Inc 10-Q for FY2026 Q3

Prime Medicine, Inc. (PRME)

10-Q 2026-11-12 For: 2026-09-30
View Original
Added on November 12, 2026

About this 10-Q

Prime Medicine, Inc filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Prime Medicine, Inc. concluded substantial doubt exists about its ability to continue as a going concern for 12 months, reporting $61.2 million in cash, cash equivalents and short-term investments as of September 30, 2026, and $74.8 million including restricted cash. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$4.21M
up 243.9% from $1.23M a year earlier
Net loss
$39.04M
compared with a net loss of $50.58M a year earlier
Diluted EPS
-$0.22
compared with -$0.32 a year earlier